Independent Medical Education Funding Grant

Independent Medical Education Funding Grant

Status: ACTIVE
Funder: The Amgen Foundation Inc
Last Updated: February 24, 2026

Summary

Amgen is a leading biotechnology company dedicated to advancing medicine through Independent Medical Education (IME). It funds accredited educational programs that empower healthcare providers to enhance patient care. IME funding supports critical areas such as oncology, bone health, cardiovascular education, and more. Amgen's commitment ensures that these educational activities remain unbiased and compliant with applicable guidelines, fostering innovation and improved health outcomes for patients worldwide.

Overview

NOTE: Requests for IME funding may be submitted at any time and for any start date, provided that the program start date is 60 days or more from the date of submission. About Amgen Amgen is one of the world’s leading biotechnology companies. Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Our belief—and the core of our strategy—is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also will help reduce the social and economic burden of disease in society today. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. Independent Medical Education Funding As part of Amgen's mission to further the advancement of medicine and healthcare, Amgen supports Independent Medical Education ("IME"). IME is professional education given by accredited medical education providers who design and implement programs totally independent of any Amgen influence, as defined by standards such as the Accreditation Council for Continuing Medical Education ("ACCME") guidelines, the FDA's Guidance: Industry Supported Scientific and Educational Activities, and the PhRMA Code. Funding requests including for live presentations, written enduring materials, online courses, and conference symposia from organizations (e.g. hospitals, universities, societies, medical-education vendors) will be reviewed and assessed in conjunction with Amgen's goal to help physicians and other healthcare professionals to obtain information and insights that contribute to the improvement of patient care and the advancement of medicine. Amgen supports IME that address: Alignment of the proposed IME program to established educational goals focused on unmet clinical, educational or professional practice needs in therapeutic areas of interest Education of health care providers including trainees, allied health professionals and payers Advancing the understanding of the disease state Improving health care providers' understanding of the diagnosis, treatment, outcomes, and co-morbidities Quality, reimbursement, access to care Innovative and biosimilar drug development Disease States and Areas of Interest: Oncology MRD in ALL (or acute leukemia) [especially if reaching pathologists and/or community oncologists] Treatment of pediatrics, AYA and adult ALL patients [especially if within global reach] Importance of biomarker testing in cancer care with emphasis on Lung, CRC or Gastric Management of ITP Management of Relapse Refractory Multiple Myeloma Bispecific T-cell Engager education in solid tumors (e.g, Lung, Prostate) Patient management and monitoring with bispecific T-cell engagers Immunotherapy in Small Cell Lung Cancer Bone Improving the awareness, diagnosis, and treatment of osteoporosis, among multiple specialties (notably primary care and orthopedics) with varying degrees of expertise including Nurse Practitioners (NPs) and Physician Assistants (PAs) New and emerging treatments in osteoporosis, including the evolved treatment paradigm of anabolic à antiresorptive for patients at very high risk of fracture Conditions other than PMO/MOP associated with bone loss and fractures: CTIBL, GIOP, OP with CKD, OP with diabetes, Osteogenesis Imperfecta, and idiopathic OP Increasing awareness of emerging AI/ML technologies designed to detect or predict osteoporotic fractures, including care pathway implementation considerations Cardiovascular & Obesity Identification and management of very high risk ASCVD patientsEducation on the implementation of the 2018 ACC/AHA Cholesterol Guidelines and the 2022 ACC ECDP Nonstatin Therapies for LDL-C in ASCVDCurrent Dyslipidemia treatment landscape and the importance and urgency of LDL-C lowering in CVDEnhancing patient access to PCSK9 inhibitors and improving Physician perceptionPrioritization of management of dyslipidemia in patients with DM and/or obesity Inflammation & Vasculitis: Education to Increase Awareness of: Rheumatologic diseases with particular interest in: Rheumatoid Arthritis, Psoriatic Arthritis,and Ankylosing Spondylitis,Dermatologic diseases focusing on psoriasis, other psoriatic diseases, atopic dermatitis, and prurigo nodularisThe OX40 pathway in inflammatory diseases (e.g., AD, PN, asthma)Respiratory diseases focusing on asthma & COPD Neuroimmunology: Education to Increase Awareness of: NMOSDStrengthen clinician understanding of the diagnosis of neuromyelitis optica spectrum disorder, including application of current diagnostic criteria and differentiation from multiple sclerosis and related disorders.Increase awareness of the burden of NMOSD, including disability, impact on vision and mobility, quality of life considerations, and ongoing unmet needs in timely diagnosis and sustained disease control.Enhance clinician knowledge of current treatment options, management strategies, and monitoring for new disease activity, including the use of imaging and biomarkers, in NMOSD gMGIncrease understanding of the heterogeneous clinical presentation and disease burden of generalized myasthenia gravis, with emphasis on ongoing unmet needs in timely diagnosis, individualized treatment selection, and long-term disease control.Enhance awareness of the immunopathology of gMG, including the contribution of B cells to autoantibody production and disease activity.Strengthen clinician knowledge of current and evolving treatment approaches for gMG, including how to appropriately transition therapies and incorporate monitoring considerations.Advance understanding of patient centered outcomes in gMG, such as quality of life, functional status, and treatment preferences, to help clinicians optimize shared decision making. Obesity: Education to Increase Awareness of: Burden of obesity, including treatment burden and persistence for patients living with obesity and related conditionsObesity pathophysiology, including GIP and GLP-1 biologyClinical diagnosis and targets in obesity care beyond weight and BMIImproving the awareness, diagnosis, and treatment of obesity and related conditions within groups that are not obesity medicine specialists e.g. primary care, cardiologists, heart failure specialists, nephrologists, sleep and liver experts etc. Oncology: Education to Increase Awareness of: MRD in ALL (or acute leukemia) [especially if reaching pathologists and/or community oncologists]Treatment of pediatrics, AYA and adult ALL patients [especially if within global reach]Importance of biomarker testing in cancer care with emphasis on Lung, CRC or GastricManagement of ITPManagement of Relapse Refractory Multiple MyelomaBispecific T-cell Engager education in solid tumors (e.g, Lung, Prostate)Patient management and monitoring with bispecific T-cell engagersImmunotherapy in Small Cell Lung Cancer Refractory Gout: Education to increase awareness of: Disease state and common comorbidities in patients with gout Pathophysiology of gout Connection between gout and CVD, CKD Evidence-based guidelines for gout management Referral pathways for patients with gout Medication non-adherence in patients with gout Systemic Inflammatory Diseases: Education to Increase Awareness of: IgG4-RDIncrease understanding of the systemic nature and clinical heterogeneity of IgG4 RD, emphasizing the importance of multidisciplinary evaluation to support timely diagnosis and comprehensive disease assessment.Enhance awareness of the immunopathology of IgG4 RD, including the role of B cells in driving plasmablast expansion, tissue inflammation, and fibrosis.Strengthen clinician knowledge of the current therapeutic landscape for IgG4 RD, including mechanisms of action and evidence supporting available treatment approaches.Advance understanding of long-term management in IgG4 RD, including monitoring disease activity, managing chronic organ involvement, optimizing maintenance therapy, and mitigating potential treatment related complications.Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: Granulomatosis with Polyangiitis (GPA) / Microscopic Polyangiitis (MPA)Recognizing GPA/MPAUrgency to Treat GPA/MPATreatment Options for GPA/MPA Thyroid Eye Disease Education to increase awareness of: Early Thyroid Eye Disease diagnosis and treatment Differentiating Thyroid Eye Disease from Grave's Disease Thyroid Eye Disease burden of illness, treatments and unmet needs Benefit-risk evaluations for clinical decision-making in patient with Thyroid Eye Disease Ultra Rare: Education to Increase Awareness of: Journey and life experiences in patients with Ultra-Rare diseases (chronic granulomatous disease, nephropathic cystinosis, and urea cycle disorders)Newborn screening, genetic testing, or diagnosis of Ultra-Rare diseasesThe importance of a multidisciplinary, collaborative clinician team (or specific clinician cohorts) for optimal outcomes in patients with Ultra-Rare diseasesTreatment paradigms and optimal management strategies for Ultra-Rare diseasesPathophysiology, disease burden, and comorbidities of Ultra-Rare diseasesImportance of adherence and compliance to medications for Ultra-Rare diseases

Eligibility

You can learn more about this opportunity by visiting the funder's website. Independent Medical Education supported by Amgen in the U.S. must be:Provided by a United States based accredited provider (e.g. ACCME, ACPE, ANCC) or other organizations authorized by state law to award continuing medical education credits. Paid to a United States based organizationAmgen's support for IME programs that meet the Eligibility Criteria is compliant with federal and state laws, as well as guidelines that govern such activities.Responsibility and control over the selection, content, faculty, educational methods, materials, and venue for an independent medical education event belongs solely to the organizers of the event in accordance with the accredited provider's guidelines. IME funding decisions will not take into account the current or potential customer status of the IME requestor.Amgen requires that a fully-executed agreement, signed by the requesting IME Provider and Amgen be completed prior to the commencement of the IME program.Amgen commercial staff, including field staff, is not involved in decisions to fund IME programs.

Ineligibility

Amgen will not provide IME funding for:Individuals Requests for payments to Individuals Fellowships Overhead Expenses General Operating Expenses Entertainment Expenses Awards/ Travel Awards Costs of travel, lodging, or other personal expenses of non-faculty individuals attending IME, either directly to the individuals participating in the event or indirectly to the event's provider. Funding cannot be used to compensate participants for time spent at the IME event. MealsAmgen does not prohibit organizers from serving meals at IME events; however, Amgen's IME funds shall not be used to provide meals at IME eventsAmgen will not provide any advice or guidance to the accredited independent medical education provider (even if asked) regarding the content or faculty for any Independent Medical Education program.